Health Experts Issue Urgent Warning Over Black Market Weight Loss Injections
Health experts have issued a stark warning that individuals purchasing weight loss injections may be completely unaware they are acquiring products from the dangerous black market. This alarming alert comes as global patents for specific pharmaceutical drugs begin to expire, triggering a significant surge in the production and distribution of unlicensed and unregulated versions of these medications.
MPs Hear Evidence on Targeting of Vulnerable Individuals
Members of Parliament have been informed that online pharmacies, operating without any proper oversight or regulation, are actively targeting vulnerable individuals. This includes young people and those with pre-existing medical conditions who may be desperately seeking solutions. The Health and Social Care Committee is currently scrutinising compelling evidence regarding the substantial health risks associated with purchasing weekly injections through online platforms and other non-medical, illicit sources.
Semaglutide Patent Expiry Fuels Mass Production
The primary active ingredient in popular treatments such as Wegovy and Ozempic is semaglutide, which is currently manufactured by the pharmaceutical giant Novo Nordisk. However, the patent for this crucial component expired in India earlier this month. This expiration has directly led to a dramatic increase in mass production from numerous local manufacturers who are now creating their own versions of the jabs.
Dr Kieran Seyan, the chief medical officer at Pharmacy2U, expressed his personal concerns to the committee, stating, "My personal concern is that we have just seen semaglutide go off licence in places like India, so this is going to be manufactured on a wide scale. It's not that it's a dodgy drug, but access to that illicit market may increase as a result."
Widespread Use and High Private Costs
Current data suggests that approximately 1.6 million people in the United Kingdom are now using these injections. The vast majority obtain them through private prescriptions. While the National Health Service is gradually increasing access for patients suffering from severe obesity, the private costs remain prohibitively high for many. Reports indicate that a monthly supply of Wegovy can range from £80 to £300 for a four-week period, depending entirely on the required dosage.
Global Patent Landscape and Market Monitoring
Additional patent expirations for semaglutide are currently unfolding in China and Brazil, with Turkey and South Africa expected to follow later this year. In contrast, patent protections in the United States and Europe are projected to remain firmly in place until at least 2031. John Spoors, from the National Institute for Health and Care Excellence (NICE), commented, "When the patent expires, the prices start to drop." A dedicated Government task force is now actively monitoring how the arrival of these cheaper 'biosimilar' products might impact the UK market.
Social Media Advertising and Serious Health Complications
The committee emphasised that the rise of unregulated 'skinny jabs' has been significantly fuelled by pervasive advertising on popular social media platforms. Tragically, serious health complications and adverse reactions have been reported following the use of unlicensed drugs obtained from these non-medical and often fraudulent sources.
Committee chair Layla Moran stated forcefully, "We are way, way behind and there are a number of families and people who are now affected by this. Young girls are finding a way [to access the drugs]... they are getting it illegally from abroad... There is huge public concern about this."
Moran further added, "We've got millions of people who are eligible on the NHS, let alone those who are after it for a bikini body who shouldn't be taking it. They are turning to the black market to do it."
MHRA Highlights Profit Margins and Safety Concerns
The Medicines and Healthcare products Regulatory Agency (MHRA) has revealed that the profit margins for illegal weight loss drugs now surpass those of some Class A substances. Authorities warn that even so-called 'genuine' products sold illicitly can be extremely unsafe due to improper storage conditions or incorrect, dangerous dosages.
Andy Morling, head of criminal enforcement at the MHRA, explained, "We have seen GLP-1 drugs that are illegally traded, but it is the genuine product. That doesn't make it safe. It hasn't been produced in accordance with genuine manufacturing processes, the sterility is questionable, or the dosage is questionable. It's absolutely not safe, but it is the genuine product."
Morling continued, "I honestly believe that a lot of the people that are buying these products from the black market, don't know they're buying from the black market. There's been a blurring of the edges between medicine and cosmetic products over the last 18 months."
Tragic Case Under Investigation
Layla Moran cited the heartbreaking case of 53-year-old Karen McGonigal. Her two daughters claim her death in May last year occurred just days after she was illegally administered a dose of semaglutide. Moran added, "It was a local Botox provider, I believe, who gave her this jab illegally, and I understand there is an ongoing investigation with Greater Manchester Police." Mr Morling praised the women for their courage in speaking publicly about their mother's tragic death.
